Категории

Dr. Tsao on Rationale for Staging Renal Cell Carcinoma

Опубликовано: 09 Март 2020
на канале: OncLive
80
1

Website: https://www.onclive.com
Twitter:   / onclive  
Facebook:   / onclive  
LinkedIn:   / onclive  

Смотрите видео Dr. Tsao on Rationale for Staging Renal Cell Carcinoma онлайн без регистрации, длительностью часов минут секунд в хорошем качестве. Это видео добавил пользователь OncLive 09 Март 2020, не забудьте поделиться им ссылкой с друзьями и знакомыми, на нашем сайте его посмотрели 80 раз и оно понравилось 1 людям.

play_arrow
389
1

How To Get Sofi Referral Bonus

How To Get Sofi Referral Bonus
play_arrow
10,675
like

CATCH (CBA 2020) - Line Dance (Jo Thompson Szymanski & Grace David)

CATCH (CBA 2020) - Line Dance (Jo Thompson Szymanski & Grace David)
play_arrow
122,630
9 тыс

You Should NEVER Visit THE BOBA TEA SHOP!

You Should NEVER Visit THE BOBA TEA SHOP!
play_arrow
235
12

НЕВОЗМОЖНАЯ КОНЦОВКА В SURVIVAL CHAOS (не 2кхаос)

НЕВОЗМОЖНАЯ КОНЦОВКА В SURVIVAL CHAOS (не 2кхаос)
play_arrow
936,070
18 тыс

Redimi2 - Maverick (Álbum completo)

Redimi2 - Maverick (Álbum completo)
play_arrow
49,200
55

Un bestiale triangolo erotico trailer

Un bestiale triangolo erotico trailer
play_arrow
29
2

NoSQL | MongoDB Setup | PyMongo Commands

NoSQL | MongoDB Setup | PyMongo Commands
play_arrow
56,175
284

Ninja ss vs RX king

Ninja ss vs RX king
Похожие видео
play_arrow
Precision Medicine in Metastatic Triple Negative Breast Cancer

Precision Medicine in Metastatic Triple Negative Breast Cancer
play_arrow
Treating Non–Small Cell Lung Cancer With an EGFR Exon 20 Insertion

Treating Non–Small Cell Lung Cancer With an EGFR Exon 20 Insertion
play_arrow
EGFR Exon 20 Mutations in Non–Small Cell Lung Cancer

EGFR Exon 20 Mutations in Non–Small Cell Lung Cancer
play_arrow
OncLive News Network On Location: ASCO 2020 Day 1

OncLive News Network On Location: ASCO 2020 Day 1
play_arrow
Diagnosis of Neurofibromatosis Type 1

Diagnosis of Neurofibromatosis Type 1
play_arrow
Dr. Lopes on the Rationale to Stop Immunotherapy After 2 Years in Lung Cancer

Dr. Lopes on the Rationale to Stop Immunotherapy After 2 Years in Lung Cancer
play_arrow
Novel Treatments in HER2-Positive Breast Cancer

Novel Treatments in HER2-Positive Breast Cancer
play_arrow
Lurbinectedin’s Role in Managing SCLC

Lurbinectedin’s Role in Managing SCLC
play_arrow
Dr. Rizvi on the Limitations of ABVD in Hodgkin Lymphoma

Dr. Rizvi on the Limitations of ABVD in Hodgkin Lymphoma
play_arrow
Therapy Options for Hepatitis B/C–Related HCC

Therapy Options for Hepatitis B/C–Related HCC
play_arrow
Treating Patients With Essential Thrombocytopenia

Treating Patients With Essential Thrombocytopenia
play_arrow
Biology of Clear Cell Renal Cell Carcinoma

Biology of Clear Cell Renal Cell Carcinoma
play_arrow
The Use of Ruxolitinib in Myelofibrosis

The Use of Ruxolitinib in Myelofibrosis
play_arrow
Current Treatment Landscape of Soft Tissue Sarcoma

Current Treatment Landscape of Soft Tissue Sarcoma
play_arrow
Diagnostic Testing Procedure for Soft Tissue Sarcoma

Diagnostic Testing Procedure for Soft Tissue Sarcoma
play_arrow
Treatment Landscape of Castrate-Resistant Prostate Cancer

Treatment Landscape of Castrate-Resistant Prostate Cancer
play_arrow
Lenalidomide in Del 5q MDS

Lenalidomide in Del 5q MDS
play_arrow
MDS: Low-Risk Disease Treatment Options

MDS: Low-Risk Disease Treatment Options
play_arrow
Neoadjuvant Treatment for Triple-Negative Breast Cancer

Neoadjuvant Treatment for Triple-Negative Breast Cancer
play_arrow
Dr. Coleman on the VELIA Trial Impact on Ovarian Cancer Practice

Dr. Coleman on the VELIA Trial Impact on Ovarian Cancer Practice
play_arrow
Dr. Tsao on Rationale for Staging Renal Cell Carcinoma

Dr. Tsao on Rationale for Staging Renal Cell Carcinoma
play_arrow
Cirrhosis Prognosis: The Child-Pugh Score

Cirrhosis Prognosis: The Child-Pugh Score
play_arrow
Dr. Tan on the Risk of Novel Coronavirus for Patients With Cancer

Dr. Tan on the Risk of Novel Coronavirus for Patients With Cancer
play_arrow
Dr. Corcoran on Targeting HER2 Amplification in CRC

Dr. Corcoran on Targeting HER2 Amplification in CRC